Evidence map›Paper›PMID 41887343›Full record

ArticlePharmacological research2026

Mechanistic insights into CAR-mediated repression of the HNF4α-FABP1 axis and inhibition of HepG2 cell proliferation.

Zhihui Li, Linhao Li, Ritika Kurian, Jean-Pierre Raufman, Hongbing Wang

Abstract read
In one paragraph

Article in Pharmacological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhihui LiDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA.
Linhao LiDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA.
Ritika KurianDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA.
Jean-Pierre RaufmanDivision of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD, USA.
Hongbing WangDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA. Electronic address: hongbing.wang@rx.umaryland.edu.

Funding

Impact of CAR and Nrf2 dual activation on cyclophosphamide bioactivation and doxorubicin detoxificationR01CA295603 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, HONGBING, XUE, FENGTIAN · 2025 to 2025
$2.8M
Novel noncanonical actions of CAR in human LiverR01CA262084 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, HONGBING · 2021 to 2025
$2.0M
BLRD VA I01 BX004890NCI NIH HHS R01 CA262084NCI NIH HHS R01 CA295603
6 · The paper itself

Abstract

The constitutive androstane receptor (CAR) modulates the transcription of numerous genes involving drug metabolism, energy homeostasis, and cell proliferation. While rodent studies suggest an oncogenic role for murine CAR in liver cancer development, emerging evidence indicates that human CAR (hCAR) may exhibit a tumor-suppressive role in hepatocellular carcinoma; notably, overexpressing hCAR suppresses human hepatoma cell proliferation. Yet, the molecular mechanisms whereby hCAR suppresses hepatoma cell proliferation are poorly understood. Our recent RNA-seq analysis of human hepatoma cells revealed that fatty acid binding protein 1 (FABP1), a pleiotropic modulator of lipid metabolism and cancer progression, was a top gene downregulated by hCAR. Here, we report a molecular mechanism whereby hCAR downregulates FABP1 expression by modulating HNF4α signaling. Knocking down hCAR expression in a HepG2-hCAR stable cell line restores the suppressed expression of FABP1 and HNF4α, while knocking down HNF4α alone is sufficient to suppress FABP1 expression. Luciferase reporter assays revealed concentration-dependent hCAR suppression of HNF4α-mediated FABP1 transactivation. This inhibitory crosstalk between hCAR and HNF4α was further confirmed by chromatin immunoprecipitation assays, where hCAR decreased HNF4α occupancy of the FABP1 promoter. Mechanistically, hCAR inhibits HNF4α expression by prompting deacetylation of histone H3 in the HNF4α P1 enhancer region, resulting in a repressive chromatin configuration and reduced HNF4α transcription. Furthermore, overexpressing FABP1 partially rescued hCAR-suppressed cell growth. Collectively, these results uncover the hCAR-HNF4α-FABP1 axis as a novel mechanism underlying hCAR-mediated gene repression.

Indexed as

Fatty Acid-Binding ProteinsHepatocyte Nuclear Factor 4Liver NeoplasmsReceptors, Cytoplasmic and NuclearCell ProliferationDown-RegulationGene Expression Regulation, NeoplasticHep G2 CellsHumansPromoter Regions, GeneticSignal TransductionFABP1 protein, humanFatty Acid-Binding ProteinsHepatocyte Nuclear Factor 4HNF4A protein, humanReceptors, Cytoplasmic and NuclearCARFABP1Gene regulationHepatoma cell proliferationHNF4α

Identifiers

PMID41887343
PMCPMC13540445

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.